Table 4.
Summary of prostate-specific antigen (PSA) response of 8 studies
| Reference No. | Baseline PSA, ng/mL | Patients evaluated for PSA decline, n | Cycles, N | Follow-up interval, weeks |
PSA decline after 1st cycle | PSA decline after completion of RLT | ||
|---|---|---|---|---|---|---|---|---|
| any PSA | >50% PSA decline | any PSA | >50% PSA decline | |||||
| [13] | Median 169 | 38 | NR | 4 | 33/38 (87%) | 24/38 (63%) | 22/38 (57.8%) | 18/38 (47.3%) |
| [14] | Median, 49.08 (range 1.20–1,300.69) | 17 | 59 | 4 | 14/17 (82.3%) | 13/17 (76.4%) | 16/17 (94.1%) | 15/17 (88.2%) |
| [15] | Median, 57.2 | 73 | 210 | 4 | NR | NR | 60/73 (82%) | 51/73 (70%) |
| [16] | Median (25–75% IQR) 222.2 (47–443.2) | 28 | 85 | 3–4 | 25/28 (89.2%) | 7/28 (25%) | 22/28 (78.6%) | 11/28 (39%) |
| [17] | Median, 176 (range 13.4–1,146) | 14 | 38 | 4–8 | 8/14 (57%) | 3/14 (21%) | NR | NR |
| [18] | Median (IQR), 158 (35–840) | 11 | 25 | 3 | NR | NR | 8/11 (72.7%) | 5/11 (46%) |
| [19] | Median (IQR), 331 (142–682) | 26 | 61 | 4–8 | NR | NR | 23/26 (95% CI 70–97%) | 17/26 (95% CI 46–81%) |
| [20] | Median (IQR), 878 (203−1,611) | 13 | NR | NR | NR | NR | 11/13 (84.6%) | 9/13 (69%) |
PSA, prostate-specific antigen; ng/mL, nanogram/milliliter; RLT, radioligand therapy; NR, not reported; IQR, interquartile range; CI, confidence interval.